CoChat

Pharmacokinetics, bioavailability and serum levels of cardiac glycosides

Open access
Smith, Thomas W. · 1985 · Journal of the American College of Cardiology

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Digoxin, the cardiac glycoside most frequently used in clinical practice in the United States, can be given orally or intravenously and has an excretory half-life of 36 to 48 hours in patients with serum creatinine and blood urea nitrogen values in the normal range. Since the drug is excreted predominantly by the kidney, the half-life is prolonged progressively with diminishing renal function, reaching about 5 days on average in patients who are essentially anephric. Serum protein binding of digoxin is only about 20%, and differs markedly in this regard from that of digitoxin, which is 97% bound by serum albumin at usual therapeutic levels. Digitoxin is nearly completely absorbed from the normal gastrointestinal tract and has a half-life averaging 5 to 6 days in patients receiving usual doses irrespective of renal function. The bioavailability of digoxin is appreciably less than that of digitoxin, averaging about two-thirds to three-fourths of the equivalent dose given intravenously in the case of currently available tablet formulations. Recent studies have shown that gut flora of about 10% of patients reduce digoxin to a less bioactive dihydro derivative. This process is sensitive to antibiotic administration, creating the potential for important interactions among drugs. Serum or plasma concentrations of digitalis glycosides can be measured by radioimmunoassay methods that are now widely available, but knowledge of serum levels does not substitute for a sound working knowledge of the clinical pharmacology of the preparation used and careful patient follow-up.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0735-1097(85)80462-9

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Lindenbaum, 1970, Impairment of digoxin absorption by neomycin (abstr), Clin Res, 20, 410

Cited by

See all 70

Metadata

Authors
Smith, T. W.
Corresponding author
Smith, Thomas W.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
1985-05
Volume
5
Issue
5
Pages
43A-50A
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2069114074
Cited by
69
References
53
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 1 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 1 · 2014: 3 · 2012: 1
FWCI
2.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords
digoxin, digitoxin, cardiac glycosides, pharmacokinetics, bioavailability, plasma protein binding, renal excretion, half-life, drug interactions, radioimmunoassay, serum concentration monitoring
MeSH terms
Absorption, Biological Availability, Cardiac Glycosides, Cost-Benefit Analysis, Digitoxin, Digoxin, Half-Life, Humans, Kinetics, Radioimmunoassay, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. https://app.cochat.ai/papers/10.1016/s0735-1097(85)80462-9
The paper
Smith, T. W. (1985). Pharmacokinetics, bioavailability and serum levels of cardiac glycosides. Journal of the American College of Cardiology. https://doi.org/10.1016/s0735-1097(85)80462-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.